Texas Yale Capital Corp. continued to hold its position in Bristol-Myers Squibb Company (NYSE:BMY) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 15,625 shares of the biopharmaceutical company’s stock at the close of the second quarter. Texas Yale Capital Corp.’s holdings in Bristol-Myers Squibb were worth $871,000 at the end of the most recent reporting period.
Other hedge funds have also recently added to or reduced their stakes in the company. Tradewinds Capital Management LLC boosted its stake in shares of Bristol-Myers Squibb by 34.6% during the 2nd quarter. Tradewinds Capital Management LLC now owns 1,945 shares of the biopharmaceutical company’s stock worth $108,000 after purchasing an additional 500 shares during the period. Welch Investments LLC lifted its holdings in Bristol-Myers Squibb by 3.9% during the 1st quarter. Welch Investments LLC now owns 2,109 shares of the biopharmaceutical company’s stock valued at $115,000 after buying an additional 79 shares in the last quarter. Blue Chip Partners Inc. lifted its holdings in Bristol-Myers Squibb by 0.8% during the 1st quarter. Blue Chip Partners Inc. now owns 2,141 shares of the biopharmaceutical company’s stock valued at $116,000 after buying an additional 17 shares in the last quarter. American National Bank lifted its holdings in Bristol-Myers Squibb by 11.7% during the 2nd quarter. American National Bank now owns 2,144 shares of the biopharmaceutical company’s stock valued at $119,000 after buying an additional 225 shares in the last quarter. Finally, Proficio Capital Partners LLC lifted its holdings in Bristol-Myers Squibb by 29.6% during the 1st quarter. Proficio Capital Partners LLC now owns 2,204 shares of the biopharmaceutical company’s stock valued at $119,000 after buying an additional 504 shares in the last quarter. 68.93% of the stock is owned by hedge funds and other institutional investors.
Bristol-Myers Squibb Company (NYSE:BMY) opened at 60.84 on Tuesday. The company’s 50 day moving average is $63.50 and its 200 day moving average is $57.74. Bristol-Myers Squibb Company has a 1-year low of $46.01 and a 1-year high of $66.10. The company has a market cap of $99.77 billion, a price-to-earnings ratio of 22.22 and a beta of 1.19.
Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $0.75 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.77 by ($0.02). Bristol-Myers Squibb had a net margin of 20.56% and a return on equity of 32.41%. The business had revenue of $5.25 billion during the quarter, compared to analysts’ expectations of $5.20 billion. During the same period in the previous year, the business posted $0.77 EPS. The company’s revenue for the quarter was up 6.7% compared to the same quarter last year. Equities research analysts forecast that Bristol-Myers Squibb Company will post $3.00 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 1st. Stockholders of record on Friday, October 6th will be paid a $0.39 dividend. This represents a $1.56 annualized dividend and a dividend yield of 2.56%. The ex-dividend date is Thursday, October 5th. Bristol-Myers Squibb’s payout ratio is 61.42%.
TRADEMARK VIOLATION NOTICE: This article was first posted by Community Financial News and is the property of of Community Financial News. If you are accessing this article on another site, it was illegally copied and reposted in violation of United States and international copyright legislation. The legal version of this article can be read at https://www.com-unik.info/2017/10/31/bristol-myers-squibb-company-bmy-stake-maintained-by-texas-yale-capital-corp.html.
BMY has been the subject of a number of research analyst reports. Credit Suisse Group reiterated a “hold” rating and set a $61.00 price objective (up previously from $58.00) on shares of Bristol-Myers Squibb in a report on Friday. Cowen and Company reiterated a “hold” rating and set a $65.00 price objective on shares of Bristol-Myers Squibb in a report on Tuesday, September 19th. Jefferies Group LLC lifted their price objective on shares of Bristol-Myers Squibb from $66.00 to $72.00 and gave the company a “buy” rating in a report on Monday, September 11th. Piper Jaffray Companies reiterated a “hold” rating and set a $60.00 price objective on shares of Bristol-Myers Squibb in a report on Friday. Finally, Leerink Swann lifted their price objective on shares of Bristol-Myers Squibb from $61.00 to $72.00 and gave the company an “outperform” rating in a report on Monday, October 23rd. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and eleven have issued a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $64.73.
In related news, SVP Joseph C. Caldarella sold 9,340 shares of the firm’s stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total value of $560,400.00. Following the sale, the senior vice president now owns 46,297 shares of the company’s stock, valued at $2,777,820. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Theodore R. Samuels II bought 6,000 shares of Bristol-Myers Squibb stock in a transaction that occurred on Wednesday, August 2nd. The stock was purchased at an average cost of $55.94 per share, for a total transaction of $335,640.00. Following the acquisition, the director now owns 18,000 shares of the company’s stock, valued at $1,006,920. The disclosure for this purchase can be found here. Company insiders own 0.23% of the company’s stock.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
What are top analysts saying about Bristol-Myers Squibb Company? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Bristol-Myers Squibb Company and related companies.